180 Life Sciences Corporate Media Kit

29 Platform Description OUR DRUGS 1. HU-436 (1) 2. Domb patent1 (2) 3. Mechoulam patent 2 (3) 4. Mechoulam patent 3 &others (3) HOW DOES IT WORK? OUR PRODUCTS: WHY MAN-MADE? • CBD signals through multiple GPCR receptors, e.g. CB2R, TRPV-1, 5HT1α, GPR55, GPR18 and others • Anti-inflammatory, analgesic and anxiolytic properties NON-PSYCHOACTIVE SCAs • Scientifically formulated analogs of CBD (SCAs) have been synthesized and patented, new formulations under analysis • Analysed in animal models of inflammation and pain • High purity (>99.5%) • CBD from plants are typically ≤ 98% pure, contain THC, minor cannabinoids, terpenes, flavonoids etc. • Consistent across batches, more favourable for obtaining regulatory approval Non-psychoactive CBD analogs (SCAs) are anti-inflammatory , and elicit analgesic effects Studied by Mechoulam, Gallily, Feldmann since 1998 (Malfait et al, PNAS 2000) (1) Patented drug we licensed from HU, but expect to discover superior drugs from ongoing research (2) CBD derivative, patent being filed, agreement with Domb & HU completed (3) Not yet filed 180 Life Sciences Corp. www.180lifesciences.com Q4 2020